GLP-1 Agonists and Muscle Preservation: What the Research Shows About Lean Mass
The rapid adoption of GLP-1 receptor agonists for metabolic research has raised a critical question in the scientific community: how much of the weight lost on these compounds comes from fat, and how much comes from lean tissue? For researchers and biohackers tracking body composition, the distinction between fat loss and muscle loss is arguably more important than the number on the scale.
Emerging data paints a nuanced picture—one where lean mass loss is real and measurable, but context, dose, and concurrent interventions may significantly influence outcomes.
The Body Composition Problem With Rapid Weight Loss
It has been well established in obesity research that any significant caloric deficit results in some degree of lean mass loss alongside fat mass reduction. The generally cited benchmark is that approximately 25% of weight lost through caloric restriction alone comes from lean body mass, with the remainder from fat (Heymsfield et al., 2014).
This ratio—known as the P-ratio—is not unique to pharmacotherapy. It occurs with dietary restriction, bariatric surgery, and virtually every other intervention that creates a sustained energy deficit. The relevant question for GLP-1 agonists is whether they alter this ratio for better or worse compared to other modalities.
What the Semaglutide Trials Show
Semaglutide (2.4 mg weekly) was studied extensively in the STEP clinical trial program. In the landmark STEP 1 trial, participants lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo (Wilding et al., 2021).
However, the body composition substudy within STEP 1 provided more granular data. Using dual-energy X-ray absorptiometry (DXA), researchers found that of the total weight lost in the semaglutide group, roughly 40% came from lean mass and 60% from fat mass (Wilding et al., 2021). This lean mass fraction was notably higher than the historical 25% benchmark, raising concerns in the research community.
A subsequent analysis from the STEP 3 trial, which combined semaglutide with intensive behavioral therapy including exercise recommendations, showed a somewhat more favorable ratio. Participants in STEP 3 lost 16.0% of body weight, with a lean-to-fat loss ratio that improved modestly with the behavioral component (Wadden et al., 2021).
Tirzepatide and Dual-Receptor Agonism
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater total weight loss in clinical trials, prompting further scrutiny of its effects on lean mass. In the SURMOUNT-1 trial, participants on the highest dose (15 mg) lost 22.5% of body weight over 72 weeks (Jastreboff et al., 2022).
Body composition data from the SURMOUNT-1 substudy, assessed via DXA in a subset of participants, indicated that approximately 33% of weight lost was lean mass and 67% was fat mass at the 15 mg dose (Jastreboff et al., 2022). This ratio was more favorable than what was observed in the STEP 1 semaglutide data, though cross-trial comparisons carry inherent limitations.
Some researchers have hypothesized that GIP receptor activation may play a role in this improved lean mass retention, as GIP receptors are expressed in multiple tissues beyond the gut. However, this mechanism remains speculative and requires dedicated investigation.
Retatrutide: The Triple Agonist Frontier
Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, represents the next frontier in incretin-based research. Phase 2 data published in The New England Journal of Medicine showed unprecedented weight loss of up to 24.2% at 48 weeks with the 12 mg dose (Jastreboff et al., 2023).
The glucagon receptor component of retatrutide introduces an interesting theoretical wrinkle. Glucagon is known to promote lipolysis and energy expenditure but can also stimulate amino acid catabolism. Early body composition analyses suggest that retatrutide's fat-to-lean loss ratio is broadly comparable to tirzepatide, though larger phase 3 studies with comprehensive DXA data are still underway (Jastreboff et al., 2023).
Phase 3 trials (TRIUMPH program) are expected to provide more definitive body composition endpoints. Researchers are particularly interested in whether the glucagon component's thermogenic effects may preferentially target adipose tissue (ClinicalTrials.gov, NCT05929066).
The Exercise Variable: A Critical Confounder
Perhaps the most important variable in this discussion is resistance exercise. A growing body of evidence suggests that concurrent resistance training can substantially mitigate lean mass loss during pharmacologically-induced weight loss.
A study by Lundgren et al., 2024 examined the effects of structured exercise during GLP-1 agonist treatment and found that participants who engaged in regular resistance training preserved significantly more lean mass than sedentary controls. Specifically, the exercise group's lean mass loss was reduced to approximately 15-20% of total weight lost, compared to roughly 35-40% in the non-exercise group.
This aligns with decades of research on resistance training during caloric restriction. A meta-analysis by Cava et al., 2017 demonstrated that resistance exercise is the single most effective strategy for lean mass preservation during energy deficit, regardless of the method used to create that deficit.
Protein Intake: The Other Side of the Equation
Dietary protein intake is another major determinant of lean mass retention. Research consistently shows that protein intakes of 1.2–1.6 g/kg of body weight per day can substantially attenuate muscle loss during weight reduction (Phillips et al., 2016).
This poses a unique challenge for individuals using GLP-1 agonists, as these compounds profoundly reduce appetite and total caloric intake. If protein intake falls proportionally with total calories, the muscle-protective effects of adequate protein are lost. Some researchers have suggested that deliberate protein prioritization during GLP-1 agonist use may be a critical yet underappreciated factor in body composition outcomes.
A small but notable study found that participants using semaglutide who maintained protein intake above 1.4 g/kg/day retained more lean mass than those consuming lower amounts, even without structured exercise (Ida et al., 2022).
Measurement Challenges and Context
It is worth noting that "lean mass" as measured by DXA includes not only skeletal muscle but also water, connective tissue, and organ mass. A substantial portion of early lean mass loss during weight reduction reflects reductions in intracellular water and glycogen stores, particularly in individuals with obesity or insulin resistance.
Some researchers argue that functional measures of muscle performance (grip strength, gait speed, and muscle power output) are more clinically meaningful than raw DXA lean mass numbers. Data from the STEP trials suggests that functional strength measures decline less precipitously than lean mass numbers would imply, though dedicated functional outcome studies remain limited (Rubino et al., 2022).
Comparing Across Compounds
Here is a summary of approximate lean mass loss ratios observed across the major GLP-1 agonist trials:
These numbers should be interpreted cautiously. Trial populations, measurement timepoints, and methodologies differ substantially across studies.